Glioblastoma Multiforme Pipeline Therapeutics and Drug Profiles Analysis 2017 - RnR Market Research

Monday, July 3, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

PUNE, India, July 3, 2017 /PRNewswire/ --

Glioblastoma Multiforme Pipeline Therapeutics Development 2017 report provides

Companies Involved in Therapeutics Development like AbbVie, Novartis AG, Novogen, Merck KGaA and others. Report encapsulates all the dormant and discontinued Glioblastoma Multiforme pipeline projects.

Glioblastoma Multiforme Pipeline Review H1

2017 provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics.

Complete report on Glioblastoma Multiforme - Pipeline Review, H1 2017 spread across 1430 pages is available at .

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 102, 55, 1, 5, 158, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 10, 15, 1, 32 and 9 molecules, respectively.

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial cells known as astrocytes. Glioblastoma Multiforme (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Companies discussed in this report include  AbbVie Inc, Actuate Therapeutics Inc, Advantagene Inc, Advenchen Laboratories LLC, Affimed GmbH, Agenus Inc, Ambrx Inc, Amgen Inc, Ampio Pharmaceuticals Inc, AngioChem Inc, Apac Biotech Pvt Ltd, apceth Biopharma GmbH, APIM Therapeutics AS, Apogenix GmbH, Ariad Pharmaceuticals Inc, Arog Pharmaceuticals Inc, Astellas Pharma Inc, AstraZeneca Plc, Athenex Inc, Autotelic Inc, Basilea Pharmaceutica Ltd, Batu Biologics Inc, Bayer AG, Beactica AB, BeiGene (Beijing) Co Ltd, Berg LLC, Bexion Pharmaceuticals LLC, BeyondSpring Pharmaceuticals Inc, Bio-Path Holdings Inc, Bioasis Technologies Inc, BioCancell Ltd, Biomar Microbial Technologies, Bioncotech Therapeutics SL, Biovista Inc, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Cantex Pharmaceuticals Inc, Cavion LLC, Celgene Corp, Celldex Therapeutics Inc, Cellmid Ltd, Celsion Corp, ChemoCentryx Inc, CLL Pharma SA, Coherus BioSciences Inc, Cortice Biosciences Inc, Critical Outcome Technologies Inc, Cynata Therapeutics Ltd, CytoVac A/S, CytRx Corp, Daiichi Sankyo Company Ltd, Deciphera Pharmaceuticals LLC, DEKK-TEC Inc, DelMar Pharmaceuticals Inc, Diffusion Pharmaceuticals Inc.

Order a copy of this research report at .

Related Report on Glioblastoma Multiforme: 

"Glioblastoma multiforme (GBM) Epidemiology forecast to 2023" provides an overview of the epidemiology trends of Glioblastoma multiforme (GBM) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Glioblastoma multiforme (GBM) prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Glioblastoma multiforme (GBM). The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by team of industry experts.

Explore more reports of Pharmaceutical Market Research at . 

About Us: is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.

Contact: Ritesh Tiwari 2nd Floor, Metropole, Bund Garden Road, Pune - 411001, India. Tel: +1-888-391-5441 E-mail:

SOURCE RnRMarketResearch

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store